Skip to main content
Print Save

Generic Vivjoa Availability

Last updated on Nov 7, 2023.

Vivjoa is a brand name of oteseconazole, approved by the FDA in the following formulation(s):

VIVJOA (oteseconazole - capsule;oral)

  • Manufacturer: MYCOVIA PHARMS
    Approval date: April 26, 2022
    Strength(s): 150MG [RLD]

Has a generic version of Vivjoa been approved?

No. There is currently no therapeutically equivalent version of Vivjoa available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vivjoa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Antifungal compounds and processes for making
    Patent 10,414,751
    Issued: September 17, 2019
    Inventor(s): Hoekstra William J. & Wirth David Dale & Ehiwe Tracy & Bonnaud Thierry
    Assignee(s): Mycovia Pharmaceuticals, Inc.

    The present invention relates to polymorphic forms of compound 1 or 1a and processes for preparing compound 1 and 1a polymorphs, which are useful as antifungal agents. In particular, the invention seeks to provide a new methodology for preparing polymorphs of compound 1 and substituted derivatives thereof.

    Patent expiration dates:

    • March 17, 2036
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Patent 11,247,981
    Issued: November 30, -0001

    Patent expiration dates:

    • May 9, 2033
      ✓ 
      Patent use: VIVJOA IS INDICATED TO REDUCE THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN FEMALES WITH A HISTORY OF RVVC WHO ARE NOT OF REPRODUCTIVE POTENTIAL
  • Metalloenzyme inhibitor compounds
    Patent 8,236,962
    Issued: August 7, 2012
    Inventor(s): Hoekstra William J. & Schotzinger Robert J. & Rafferty Stephen W.
    Assignee(s): Viamet Pharmaceuticals, Inc.

    The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

    Patent expiration dates:

    • April 22, 2031
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Metalloenzyme inhibitor compounds
    Patent 8,754,227
    Issued: June 17, 2014
    Inventor(s): Hoekstra William J. & Schotzinger Robert J. & Rafferty Stephen W.
    Assignee(s): Viamet Pharmaceuticals, Inc.

    The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

    Patent expiration dates:

    • April 22, 2031
      ✓ 
      Patent use: VIVJOA IS INDICATED TO REDUCE THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN FEMALES WITH A HISTORY OF RVVC WHO ARE NOT OF REPRODUCTIVE POTENTIAL
  • Antifungal compounds and processes for making
    Patent 9,840,492
    Issued: December 12, 2017
    Inventor(s): Hoekstra William J. & Wirth David Dale & Ehiwe Tracy & Bonnaud Thierry
    Assignee(s): Viamet Pharmaceuticals, Inc.

    The present invention relates to polymorphic forms of compound 1 or 1a and processes for preparing compound 1 and 1a polymorphs, which are useful as antifungal agents. In particular, the invention seeks to provide a new methodology for preparing polymorphs of compound 1 and substituted derivatives thereof.

    Patent expiration dates:

    • March 17, 2036
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • April 26, 2027 - NEW CHEMICAL ENTITY
    • April 26, 2032 - GENERATING ANTIBIOTIC INCENTIVES NOW

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer